108 related articles for article (PubMed ID: 12680233)
1. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma.
Visca P; Sebastiani V; Pizer ES; Botti C; De Carli P; Filippi S; Monaco S; Alo PL
Anticancer Res; 2003; 23(1A):335-9. PubMed ID: 12680233
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue.
Alò PL; Visca P; Botti C; Galati GM; Sebastiani V; Andreano T; Di Tondo U; Pizer ES
Am J Clin Pathol; 2001 Jul; 116(1):129-34. PubMed ID: 11447743
[TBL] [Abstract][Full Text] [Related]
3. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival.
Younes M; Juarez D; Lechago LV; Lerner SP
Anticancer Res; 2001; 21(1B):575-8. PubMed ID: 11299807
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma.
Visca P; Sebastiani V; Botti C; Diodoro MG; Lasagni RP; Romagnoli F; Brenna A; De Joannon BC; Donnorso RP; Lombardi G; Alo PL
Anticancer Res; 2004; 24(6):4169-73. PubMed ID: 15736468
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
6. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
7. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma.
Mineta H; Miura K; Takebayashi S; Misawa K; Araki K; Misawa Y; Ueda Y
Anticancer Res; 2002; 22(6B):3489-94. PubMed ID: 12552944
[TBL] [Abstract][Full Text] [Related]
9. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
11. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
[TBL] [Abstract][Full Text] [Related]
15. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
16. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
17. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
19. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
20. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
